Tevogen (TVGN) Operating Leases (2023 - 2026)

Tevogen Bio Holdings' (TVGN) quarterly Operating Leases came in at $1.1 million in Q1 2026, down 2.56% on a QoQ basis from $1.1 million in Q4 2025.

Tevogen (TVGN) Operating Leases (2023 - 2026) Analysis & Trends

Tevogen Bio Holdings (TVGN) has 4 years of Operating Leases data on file, last reported at $1.1 million in Q1 2026.

Quarterly Operating Leases changed N/A year-over-year to $1.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.1 million (changed N/A YoY) and the FY2025 annual result came in at $1.1 million, up 19271.12% from the prior year.
Operating Leases eased to $1.1 million in Q1 2026, from $1.1 million in the prior quarter.
In the past five years, Operating Leases ranged from a high of $1.2 million in Q2 2025 to a low of $5796.0 in Q4 2024.
A 4-year average of $565688.4 and a median of $234858.0 in 2023 frame the typical range for Operating Leases.
Annual changes were most pronounced in 2024 — Operating Leases plunged 97.53% — and 2025, when it jumped 19271.12%.
Tracing TVGN's Operating Leases over 4 years: stood at $234858.0 in 2023, then sank by 97.53% to $5796.0 in 2024, then jumped by 19271.12% to $1.1 million in 2025, then dropped by 2.56% to $1.1 million in 2026.
The last three Operating Leases figures came in at $1.1 million (Q1 2026), $1.1 million (Q4 2025), and $1.2 million (Q3 2025), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.66 Bn	131.81 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	86.52 Bn	78.52 Bn	3.93 Bn
3	Argenx Se	65.30 Bn	60.11 Bn	1.37 Bn
4	Moderna	59.18 Bn	54.04 Bn	52.00 Mn
5	BeOne Medicines	42.08 Bn	36.98 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.77 Bn	28.46 Bn	992.69 Mn
7	BioNTech SE	28.13 Bn	9.74 Bn	668.28 Mn
8	Insmed	27.51 Bn	26.35 Bn	358.27 Mn
9	Royalty Pharma	27.16 Bn	26.32 Bn	-
10	Tevogen	26.21 Mn	26.21 Mn	-

Download Data